The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer

This study is currently recruiting participants.

Verified by Alberta Cancer Board, April 2007

Sponsored by:	Alberta Cancer Board
Information provided by:	Alberta Cancer Board
ClinicalTrials.gov Identifier:	NCT00126802

Purpose

Helical tomotherapy is being used to treat the prostate gland, local rates of spread and regional lymph nodes whilst sparing gross structures. The radiation to the gross disease in the prostate is hypofractionated and dose escalated. Magnetic resonance spectroscopic imaging (MRSI) is incorporated into pre- and post-treatment evaluation.

Condition	Intervention	Phase
Prostate Cancer	Procedure: Tomotherapy	Phase I Phase II

MedlinePlus related topics: Cancer Nuclear Scans Prostate Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer

Further study details as provided by Alberta Cancer Board:

Primary Outcome Measures:

rectal toxicity

Secondary Outcome Measures:

prostate-specific antigen (PSA) and MRSI disease control

Estimated Enrollment:	50
Study Start Date:	April 2005

Eligibility

Ages Eligible for Study:	up to 75 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

High risk localized prostate cancer

Exclusion Criteria:

Low/intermediate risk, metastatic cancer
Patient refusal

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126802

Contacts

Contact: Robert Pearcey, MD

780-432-8749

robertpe@cancerboard.ab.ca

Locations

Canada, Alberta
Cross Cancer Institute	Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca
Principal Investigator: Robert Pearcey, MD

Sponsors and Collaborators

Alberta Cancer Board

Investigators

Principal Investigator:

Robert Pearcey, MD

Alberta Cancer Board

More Information

Study ID Numbers:	GU-06-0052
Study First Received:	August 3, 2005
Last Updated:	September 22, 2008
ClinicalTrials.gov Identifier:	NCT00126802
Health Authority:	Canada: Health Canada

Keywords provided by Alberta Cancer Board:

tomotherapy
MRSZ
high risk prostate cancer

Study placed in the following topic categories:

Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009